Literature DB >> 23069071

High-mobility-group box protein 1A box reduces development of sodium laurate-induced thromboangiitis obliterans in rats.

Xiangqian Kong1, Hai Yuan, Xuejun Wu, Jingyong Zhang, Hua Zhou, Maohua Wang, Yang Liu, Xing Jin.   

Abstract

OBJECTIVE: High-mobility-group box protein 1 (HMGB1), as a late mediator of inflammation, plays a key role in inflammatory responses by inducing and extending the production of proinflammatory cytokines. The effect of HGMB1 in the inflammatory disease thromboangiitis obliterans (TAO) is unknown. We aimed to investigate the role of HMGB1 in sodium laurate-induced TAO in rats.
METHODS: Male Wistar rats were randomly divided into five groups (n=8 each) for treatment: normal, sham-operated, TAO model, and low-dose (15 mg/kg) or high-dose (30 mg/kg) recombinant A box (rA box) infection (administered intraperitoneally once daily for 15 days). The TAO model was induced by sodium laurate and graded by gross appearance on day 15 after femoral artery injection. Histologic changes were measured by histopathology in rat femoral arteries. Plasma levels of HMGB1, thromboxane B2, 6-keto-prostaglandin F1-α, and blood cell counts and blood coagulation levels were measured. Expression of HMGB1, receptor for advanced glycation end-products (RAGE), interleukin-6, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 was assessed by immunohistochemistry and immunofluorescence, Western blot analysis, and quantitative reverse-transcription polymerase chain reaction.
RESULTS: The typical signs and symptoms of TAO were observed on day 15 after sodium laurate injection. The expression of HMGB1, RAGE, interleukin-6, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 was markedly increased in rat femoral arteries. Plasma levels of HMGB1 and thromboxane B2 were elevated, but the level of 6-keto-prostaglandin F1-α was decreased. Blood was in a hypercoagulable state, and prothrombin, thrombin, and activated partial thromboplastin times were all significantly shortened, whereas fibrinogen level was increased in TAO rats compared with sham-operated rats. These effects were terminated by the HMGB1 antagonist rA box.
CONCLUSIONS: HMGB1 is involved in the inflammatory state in a model of TAO induced by sodium laurate in rats, probably via its receptor RAGE. As the antagonist of HMGB1, rA box can attenuate the development of TAO, which may be a potential therapeutic target for the treatment of TAO.
Copyright © 2013 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23069071     DOI: 10.1016/j.jvs.2012.06.083

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

Review 1.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

2.  Expression and purification of functional HMGB1 A box by fusion with SUMO.

Authors:  Wen-Song Ge; Jian-Gao Fan; Ying-Wei Chen; Lei-Ming Xu
Journal:  Mol Med Rep       Date:  2015-09-09       Impact factor: 2.952

3.  TLR4-mediated NF-κB signaling pathway mediates HMGB1-induced pancreatic injury in mice with severe acute pancreatitis.

Authors:  Gang Li; Xuejun Wu; Le Yang; Yuxiang He; Yang Liu; Xing Jin; Hai Yuan
Journal:  Int J Mol Med       Date:  2015-11-13       Impact factor: 4.101

4.  Levistilide A Ameliorates NLRP3 Expression Involving the Syk-p38/JNK Pathway and Peripheral Obliterans in Rats.

Authors:  Huining Guo; Li Sun; Shuang Ling; Jin-Wen Xu
Journal:  Mediators Inflamm       Date:  2018-08-12       Impact factor: 4.711

5.  Effect of AMPK signal pathway on pathogenesis of abdominal aortic aneurysms.

Authors:  Le Yang; Lin Shen; Peixian Gao; Gang Li; Yuxiang He; Maohua Wang; Hua Zhou; Hai Yuan; Xing Jin; Xuejun Wu
Journal:  Oncotarget       Date:  2017-10-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.